WO2020186158A3 - Prame binding molecules and uses thereof - Google Patents

Prame binding molecules and uses thereof Download PDF

Info

Publication number
WO2020186158A3
WO2020186158A3 PCT/US2020/022628 US2020022628W WO2020186158A3 WO 2020186158 A3 WO2020186158 A3 WO 2020186158A3 US 2020022628 W US2020022628 W US 2020022628W WO 2020186158 A3 WO2020186158 A3 WO 2020186158A3
Authority
WO
WIPO (PCT)
Prior art keywords
prame
binding molecules
compositions
cells
monitoring
Prior art date
Application number
PCT/US2020/022628
Other languages
French (fr)
Other versions
WO2020186158A2 (en
Inventor
Hans David Staffan ULMERT
Richard John O'REILLY
Kjell Torsten SJOSTROM
Original Assignee
Ulmert Hans David Staffan
Oreilly Richard John
Sjostrom Kjell Torsten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulmert Hans David Staffan, Oreilly Richard John, Sjostrom Kjell Torsten filed Critical Ulmert Hans David Staffan
Publication of WO2020186158A2 publication Critical patent/WO2020186158A2/en
Publication of WO2020186158A3 publication Critical patent/WO2020186158A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The present invention provides various PRAME binding molecules (including antibodies, antibody fragments, chimeric antigen receptors, and the like), compositions and cells comprising such PRAME binding molecules, and methods of using such PRAME binding molecules, compositions and cells, for example in the detection and/or monitoring of PRAME-positive tumors.
PCT/US2020/022628 2019-03-13 2020-03-13 Prame binding molecules and uses thereof WO2020186158A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817994P 2019-03-13 2019-03-13
US62/817,994 2019-03-13

Publications (2)

Publication Number Publication Date
WO2020186158A2 WO2020186158A2 (en) 2020-09-17
WO2020186158A3 true WO2020186158A3 (en) 2020-10-22

Family

ID=72427114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/022628 WO2020186158A2 (en) 2019-03-13 2020-03-13 Prame binding molecules and uses thereof

Country Status (1)

Country Link
WO (1) WO2020186158A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217738A1 (en) 2021-05-05 2022-05-04 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100135996A1 (en) * 2006-11-02 2010-06-03 Isabelle Teulon Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type ii receptor (amhr-ii)
US20170166634A1 (en) * 2014-05-02 2017-06-15 Medimmune Limited Ion channel modulators and uses thereof
US20180148503A1 (en) * 2015-05-22 2018-05-31 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a prame peptide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100135996A1 (en) * 2006-11-02 2010-06-03 Isabelle Teulon Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type ii receptor (amhr-ii)
US20170166634A1 (en) * 2014-05-02 2017-06-15 Medimmune Limited Ion channel modulators and uses thereof
US20180148503A1 (en) * 2015-05-22 2018-05-31 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a prame peptide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AARON CHANG, TAO DAO, PHD, ANDREW SCOTT, LEONID DUBROVSKY, MD, CHENG LIU, PHD, DAVID A. SCHEINBERG, MD PHD: "A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias", BLOOD, vol. 126, no. 23, 3 December 2015 (2015-12-03), pages 2527, XP055754957 *
DMITRY PANKOV, LUDVIG SJÖSTRÖM, TEJA KALIDINDI , SANG-GYU LEE, KJELL SJÖSTRÖM , RUI GARDNER , MICHAEL R MCDEVITT, RICHARD O'REILL: "In vivo immuno-targeting of an extracellular epitope uf membrane bound preferentially expressed antigen in melanoma (PRAME", ONCOTARGET, vol. 8, no. 39, 26 July 2017 (2017-07-26), pages 65917 - 65931, XP055749204 *

Also Published As

Publication number Publication date
WO2020186158A2 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2019013033A (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof.
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
BR112018070823A2 (en) anti-human sirpa antibody or antigen-binding fragment thereof or antigen-binding antibody mimetic, pharmaceutical composition, combination product, isolated nucleic acid molecule, vector, isolated host cell, polypeptide, methods for making an antibody, in in vitro or ex vivo to determine sirp positive, diagnostic and predictive response cells of a subject, and use of an anti-sirp antibody or antigen-binding fragment thereof or an antibody-binding mimetic in vitro or ex vivo of at least one anti-human sirpa antibody or antigen binding fragment thereof or antigen binding antibody mimetic.
WO2017181139A3 (en) Anti-human vista antibodies and use thereof
WO2020082209A8 (en) Anti-cldn18.2 antibody and uses thereof
WO2019014328A3 (en) Agonist antibodies that bind human cd137 and uses thereof
WO2016172703A3 (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
WO2021097365A3 (en) Antigen-binding proteins targeting shared neoantigens
MX2018012651A (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies.
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
WO2020139926A3 (en) Anti-ctla4 antibodies and methods of use thereof
WO2018069871A3 (en) Anti-kras binding proteins
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
WO2016154623A3 (en) Anti-cd133 monoclonal antibodies and related compositions and methods
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
WO2018071583A3 (en) Humanized anti-muc1* antibodies and use of cleavage enzyme
EP3873940A4 (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2020239895A3 (en) Detection of colorectal cancer
WO2021207948A9 (en) Anti-sars-cov-2 antibodies and uses thereof
WO2020223392A3 (en) Cancer associated antibody compositions and methods of use
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
MX2021002750A (en) Anti-tnfrsf9 antibodies and uses thereof.
WO2017200981A8 (en) Anti-factor ix padua antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20769338

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20769338

Country of ref document: EP

Kind code of ref document: A2